Joint Formulary & PAD

Adalimumab - Hidradenitis suppurativa

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Associated Icons :
BNF SPC
NHSE
R
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Adalimumab
Indication :
Hidradenitis suppurativa
Group Name :
Keywords :
Brand Names Include :
Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Adalimumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hidradenitis suppurativa.

Committee Recommendations (1)

16 Apr 18 - Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.